Once a pharmaceutical buys a licence, how are you going to stop them from what you might call “exploitation”, although they would just call “profitability”?
October 18th, 2018 / 10:30 a.m.
Chatham-Kent—Leamington, CPC
Once a pharmaceutical buys a licence, how are you going to stop them from what you might call “exploitation”, although they would just call “profitability”?
See context to find out what was said next.